Poseida Therapeutics, Inc. (PSTX)

Market Cap	921.06M
Revenue (ttm)	150.86M
Net Income (ttm)	-60.76M
Shares Out	97.47M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,978,863
Open	9.38
Previous Close	9.41
Day's Range	9.36 - 9.49
52-Week Range	1.87 - 9.58
Beta	1.64
Analysts	Hold
Price Target	9.00 (-4.76%)
Earnings Date	Nov 7, 2024

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple my...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 330
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTX
• Website: https://poseida.com

Financial Performance

In 2023, Poseida Therapeutics's revenue was $64.70 million, a decrease of -50.42% compared to the previous year's $130.49 million. Losses were -$123.43 million, 92.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for PSTX stock is "Hold." The 12-month stock price forecast is $9.0, which is a decrease of -4.76% from the latest price.

Price Target

$9.0

(-4.76% downside)

Analyst Consensus: Hold